The differential OTC expression between hMSCs and T-ALL cells during BCT-100 treatment suggested that hMSCs could potentially protect T-ALL cells from BCT-100 treatment by their sustained OTC expression. This evidence concerns the gene OTC and acute lymphoblastic leukemia.